De novo RUNX1-driven acute myeloid leukemia requiring integrative genetics

Celeste C Eno1, Jeremy Lorber2, Eric Vail1

  • 1Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Cancer Genetics
|February 9, 2025
PubMed
Summary

A RUNX1 deletion drove acute myeloid leukemia in a patient without prior myeloid neoplasm. Multiple tests were needed, revealing the adverse prognosis associated with RUNX1 deletion AML.